NAN-190 hydrobromide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525781

CAS#: 115388-32-4

Description: NAN-190 hydrobromide is a potent 5-HT1A receptor antagonist.


Price and Availability

Size
Price

Size
Price

Size
Price

NAN-190 hydrobromide is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 525781
Name: NAN-190 hydrobromide
CAS#: 115388-32-4
Chemical Formula: C23H28BrN3O3
Exact Mass: 473.1314
Molecular Weight: 474.399
Elemental Analysis: C, 58.23; H, 5.95; Br, 16.84; N, 8.86; O, 10.12


Synonym: NAN-190 hydrobromide

IUPAC/Chemical Name: 2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)isoindoline-1,3-dione hydrobromide

InChi Key: AXRUEPFPTQYHQD-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H27N3O3.BrH/c1-29-21-11-5-4-10-20(21)25-16-14-24(15-17-25)12-6-7-13-26-22(27)18-8-2-3-9-19(18)23(26)28;/h2-5,8-11H,6-7,12-17H2,1H3;1H

SMILES Code: O=C1N(CCCCN2CCN(C3=CC=CC=C3OC)CC2)C(C4=C1C=CC=C4)=O.[H]Br


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Fajemiroye JO, Galdino PM, Florentino IF, Da Rocha FF, Ghedini PC, Polepally PR, Zjawiony JK, Costa EA. Plurality of anxiety and depression alteration mechanism by oleanolic acid. J Psychopharmacol. 2014 Oct;28(10):923-34. doi: 10.1177/0269881114536789. Epub 2014 Jun 11. PubMed PMID: 24920136.

2: Eyhani-Rad S, Mohajjel Nayebi A, Mahmoudi J, Samini M, Babapour V. Role of 5-Hydroxytryptamine 1A Receptors in 6-Hydroxydopmaine-induced Catalepsy-like Immobilization in Rats: a Therapeutic Approach for Treating Catalepsy of Parkinson's Disease. Iran J Pharm Res. 2012 Fall;11(4):1175-81. PubMed PMID: 24250551; PubMed Central PMCID: PMC3813151.

3: Xu WJ, Zhao Y, Huo FQ, Du JQ, Tang JS. Involvement of ventrolateral orbital cortex 5-HT 1-7 receptors in 5-HT induced depression of spared nerve injury allodynia. Neuroscience. 2013 May 15;238:252-7. doi: 10.1016/j.neuroscience.2013.02.036. Epub 2013 Feb 26. PubMed PMID: 23485814.

4: Zhang Y, Zhang RX, Zhang M, Shen XY, Li A, Xin J, Ren K, Berman BM, Tan M, Lao L. Electroacupuncture inhibition of hyperalgesia in an inflammatory pain rat model: involvement of distinct spinal serotonin and norepinephrine receptor subtypes. Br J Anaesth. 2012 Aug;109(2):245-52. doi: 10.1093/bja/aes136. Epub 2012 May 23. PubMed PMID: 22628394; PubMed Central PMCID: PMC3393079.

5: Mahmoudi J, Mohajjel Nayebi A, Reyhani-Rad S, Samini M. Fluoxetine improves the effect of levodopa on 6-hydroxy dopamine-induced motor impairments in rats. Adv Pharm Bull. 2012;2(2):149-55. doi: 10.5681/apb.2012.023. Epub 2012 Jun 15. PubMed PMID: 24312786; PubMed Central PMCID: PMC3846000.

6: Sharifi H, Mohajjel Nayebia A, Farajnia S. The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats. Adv Pharm Bull. 2012;2(1):127-31. doi: 10.5681/apb.2012.019. Epub 2012 May 15. PubMed PMID: 24312782; PubMed Central PMCID: PMC3846020.

7: Mahmoudi J, Nayebi AM, Samini M, Reyhani-Rad S, Babapour V. Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats. Pharmacol Rep. 2011;63(4):908-14. PubMed PMID: 22001978.

8: Zhang Y, Li A, Xin J, Lao L, Ren K, Berman BM, Tan M, Zhang RX. Involvement of spinal serotonin receptors in electroacupuncture anti-hyperalgesia in an inflammatory pain rat model. Neurochem Res. 2011 Oct;36(10):1785-92. doi: 10.1007/s11064-011-0495-1. Epub 2011 May 10. PubMed PMID: 21556842; PubMed Central PMCID: PMC3581079.

9: Mahmoudi J, Mohajjel Nayebi A, Samini M, Reyhani-Rad S, Babapour V. 5-HT(1A) receptor activation improves anti-cataleptic effects of levodopa in 6-hydroxydopamine-lesioned rats. Daru. 2011;19(5):338-43. PubMed PMID: 22615679; PubMed Central PMCID: PMC3304392.

10: Huo FQ, Huang FS, Lv BC, Chen T, Feng J, Qu CL, Tang JS, Li YQ. Activation of serotonin 1A receptors in ventrolateral orbital cortex depresses persistent nociception: a presynaptic inhibition mechanism. Neurochem Int. 2010 Dec;57(7):749-55. doi: 10.1016/j.neuint.2010.08.011. Epub 2010 Sep 8. PubMed PMID: 20813144.

11: Nayebi AM, Rad SR, Saberian M, Azimzadeh S, Samini M. Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT(1A) receptors in rats. Pharmacol Rep. 2010 Mar-Apr;62(2):258-64. PubMed PMID: 20508280.

12: Smith VM, Hagel K, Antle MC. Serotonergic potentiation of photic phase shifts: examination of receptor contributions and early biochemical/molecular events. Neuroscience. 2010 Jan 13;165(1):16-27. doi: 10.1016/j.neuroscience.2009.09.068. Epub 2009 Sep 30. PubMed PMID: 19799970.

13: Ita ML, Cortés Mdel C, Valencia J, Eguibar JR. Activation of serotonin 5-HT1-receptors decreased gripping-induced immobility episodes in taiep rats. Neurosci Lett. 2009 Jan 9;449(2):147-50. doi: 10.1016/j.neulet.2008.10.088. Epub 2008 Oct 30. PubMed PMID: 18996171.

14: Lee JJ, Hahm ET, Lee CH, Cho YW. 5-HT1A receptor-mediated activation of a G-protein-coupled inwardly rectifying K+ current in rat medial preoptic area neurons. Eur J Pharmacol. 2008 May 31;586(1-3):114-22. doi: 10.1016/j.ejphar.2008.02.051. Epub 2008 Mar 4. PubMed PMID: 18367171.

15: Qu CL, Huo FQ, Huang FS, Li YQ, Tang JS, Jia H. The role of 5-HT receptor subtypes in the ventrolateral orbital cortex of 5-HT-induced antinociception in the rat. Neuroscience. 2008 Mar 18;152(2):487-94. doi: 10.1016/j.neuroscience.2007.09.036. Epub 2007 Sep 21. PubMed PMID: 18295406.

16: Lee JJ, Hahm ET, Lee CH, Cho YW. Serotonergic modulation of GABAergic and glutamatergic synaptic transmission in mechanically isolated rat medial preoptic area neurons. Neuropsychopharmacology. 2008 Jan;33(2):340-52. Epub 2007 Mar 28. PubMed PMID: 17392733.

17: Sapronov NS, Fedotova YO, Losev NA. Combined administration of NAN-190 and 17beta-estradiol abolishes the amnesic effect of scopolamine in middle-aged ovariectomized rats. Bull Exp Biol Med. 2006 Jul;142(1):80-2. English, Russian. PubMed PMID: 17369909.

18: Siddiqui EJ, Shabbir M, Mikhailidis DP, Thompson CS, Mumtaz FH. The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation. J Urol. 2006 Oct;176(4 Pt 1):1648-53. PubMed PMID: 16952708.

19: Siddiqui EJ, Shabbir MA, Mikhailidis DP, Mumtaz FH, Thompson CS. The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. BJU Int. 2006 Mar;97(3):634-9. PubMed PMID: 16469039.

20: Hsiao CF, Wu N, Chandler SH. Voltage-dependent calcium currents in trigeminal motoneurons of early postnatal rats: modulation by 5-HT receptors. J Neurophysiol. 2005 Sep;94(3):2063-72. Epub 2005 Jun 22. PubMed PMID: 15972834.